The talk of the show?
![](/46/pdcnewsitem/08/05/05/CPhI-WW-CPhI.jpg)
Outsourcing, biologics, generics and patient compliance look set to get tongues wagging at this year's CPHI WW.
Ahead of CPHI Worldwide in Frankfurt next week, Barbara Morgan, Pharmaceutical Business Director at Lubrizol Life Science Health discusses the trends she expects to be the talk of the show.
What do you think will be the major trends and talking points at CPHI Worldwide 2019?
We expect to see a continuation of the growing trend of outsourcing the full spectrum of pharmaceutical services, including commercial manufacturing. Recent figures show that only around one third of manufacturing — whether in the development stages or after commercial launch — is conducted in-house. This year, we have invested in our own commercial manufacturing capabilities with the opening of a new commercial manufacturing facility which is now up and running and recently produced its first set of three registration batches.
The ongoing growth of the biologics market over the past few years will likely be reflected on the show floor, particularly as 2019 has witnessed the FDA releasing guidelines on how biosimilars can achieve an interchangeable status and substitute the reference biologic without a prescriber intervening.
There has also been much discussion this year about the pricing pressures on generics, with regulators, patients and politicians seeking to drive down prices.
In terms of drug development trends, we expect to see an increased focus on long-acting products such as microparticle depots and implants as drug developers seek dosage forms that can aid better patient compliance. This is a topic we are keen to discuss with visitors to our stand.
What is your company hoping to achieve at this year's event?
This year we’re hoping to engage in discussions that center around GMP for clinical trial supply and commercial manufacturing. Lubrizol Life Science Health is currently well known for its focus on complex drug development projects. We’re keen to expand our client base and engage with those who are not yet familiar with our unique capabilities around commercial manufacturing of small batch size products.
What do you most look forward to about CPHI?
I enjoy how well-organized and efficient the CPHI Worldwide event is and the fact that it brings so many people in the industry together, giving you an opportunity to catch up with those clients that you don’t often see in person. It also provides a great environment for meeting new clients and prospects and learning more about the latest trends and talking points in the industry among like-minded peers.
Any presentations/events or news you'd like to tell us about?
This year our big announcement is that we will be changing our name from Particle Sciences to Lubrizol Life Science Health. The name change is an outward sign of our official transition under the Lubrizol Life Science brand umbrella.
As part of Lubrizol Life Science, we can share and draw upon the resources that come with being part of a large corporation, providing customers with greater support and market insights that help them meet their goals.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance